Click the blue text to follow us With the advent of biomarker-guided personalized targeted therapies and immune checkpoint inhibitors, the treatment of non-small cell lung cancer (NSCLC) continues to undergo transformation. Recently, antibody-drug conjugates (ADCs) have brought revolutionary new hope, such as trastuzumab-deruxtecan (T-DXd) being used for previously treated HER2 (ERBB2) mutated advanced NSCLC, which … Read more
Let’s take a look at the recent hot topic of ADC drugs, and systematically learn about the review published in CancersAntibody–Drug Conjugates for the Treatment of Breast Cancer. Abstract Currently, besides endocrine therapy and targeted drugs, metastatic breast cancer (BC) commonly uses chemotherapy as a treatment method. However, the lack of tumor specificity and toxicity … Read more
Following the era of chemotherapy, targeted therapy, and immunotherapy, cytotoxic drugs conjugated with targeted monoclonal antibodies have opened a new era in tumor treatment with the ADC drug class, achieving remarkable results. They have now become a significant category of new drugs in cancer treatment both domestically and internationally. So what exactly are ADC drugs? … Read more
Introduction ADC drugs are a class of highly promising anti-tumor drugs that are rapidly developing. Although 14 ADCs have been officially approved, the complex structure of ADCs poses significant challenges in the development and optimization of new ADC drugs. Studying the “structure-activity relationship” of ADC drugs and understanding the intrinsic connection between the efficacy/safety of … Read more
Abstract:Gastric cancer is a refractory malignant tumor, ranking fifth in incidence and third in mortality worldwide. Despite various treatment options significantly improving the prognosis of advanced gastric cancer (AGC), survival rates remain unsatisfactory. Therefore, the development of new therapeutic drugs is crucial for enhancing long-term efficacy. Antibody-drug conjugates (ADCs) are innovative and effective anti-tumor drugs … Read more
To build a global highland for the future ADC/RDC industry, Chengdu Medical City plans to hold the first Future XDC New Drug Conference from April 18 to 19, 2024! The conference, themed “Co-creating the Future of the Conjugated Drug Industry,” is organized by Tongxi Yi Planning, featuring a main forum and nine thematic forums. Experts … Read more
Breast cancer is the leading cause of death among women in China and worldwide. When breast cancer spreads to other parts of the body, the prognosis is poor. Currently, there is no treatment for metastatic breast cancer. Antibody-drug conjugates (ADCs) are a new type of anticancer drug consisting of antibodies, linkers, and cytotoxic agents [1]. … Read more
Let’s take a moment to focus on the recent hot topic of Antibody–Drug Conjugates and systematically learn about the review published in Cancers: Antibody–Drug Conjugates for the Treatment of Breast Cancer. Abstract Currently, aside from endocrine therapy and targeted drugs, the common treatment method for metastatic breast cancer (BC) is chemotherapy. However, the lack of … Read more
This article is compiled from Professor Song Zhengbo of Zhejiang Provincial Cancer Hospital.“Current Status and Development Challenges of ADC Drugs”. Song Zhengbo Doctor of Oncology, Associate Chief Physician, Associate Professor, Master’s Supervisor More than 100 years ago, the father of immunology, Paul Ehrlich, first proposed the concept of “magic bullet,” which refers to selectively delivering … Read more
Bispecific antibodies are antibodies that can bind to two different antigens simultaneously, providing greater flexibility in their mechanisms of action. Bispecific antibodies have achieved success in hematologic malignancies, with two bispecific antibodies already approved for market: blinatumomab, targeting CD19/CD3, and Mosunetuzumab, targeting CD20/CD3. Additionally, numerous bispecific antibodies targeting hematologic cancers have shown impressive efficacy in … Read more